Business
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics
Wize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics.
About this update from Cnbx Pharmaceuticals Inc.
[{"type":"text","content":"\n\n\n\nWize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics\n\n/* Style Definitions */\nspan.prnews_span\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\na.prnews_a\n{\ncolor:blue;\n}\nli.prnews_li\n{\nfont-size:8pt;\nfont-family:\"Arial\";\ncolor:black;\n}\np.prnews_p\n{\nfont-size:0.62em;\nfont-family:\"Arial\";\ncolor:black;\nmargin:0in;\n}\n\n\n\n\n\n\nWize Pharma, Inc. Closes Deal to Launch Joint Venture With Cannabics\nCompanies Will Launch New Entity to Research and Develop Cannabinoid Formulations to Treat Ophthalmic Conditions\nPR Newswire\nHOD HASHARON, Israel, March 6, 2019\n\n\n\nHOD HASHARON, Israel, March 6, 2019  /PRNewswire/ -- Wize Pharma, Inc. (\"Wize Pharma\" or the \"Company\") (OTCQB: WIZP) a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced that the Company closed a deal with Cannabics Pharmaceuticals Inc. (\"Cannabics\") (OTCQB:  CNBX), a world leader in personalized cannabinoid medicine focused on cancer and its side effects, to form a new entity focused on the research and development of cannabinoid formulations to treat ophthalmic conditions across a range of disease and illness categories.  \n\n \n \n\n \n\"We are very excited to announce the closing of this deal.  As Wize Pharma continues to develop its own portfolio, focused on non-cannabinoid ophthalmic conditions, our joint venture with Cannabics will pursue therapeutic pathways with cannabinoids, supported by a growing body of research that indicates cannabinoid-based therapies have the potential to address significant unmet medical needs in the market,\" said Wize's Chairman, Noam Danenberg.  \"Cannabics is a leader in the therapeutic development of cannabinoid products for oncology.  Together, we have significant expertise to effectively identify and develop new potential therapeutics to support eye health.\"\nAs a condition of closing, the companies engaged a third-party expert to evaluate and make recommendations for a viable development and regulatory pathway for eyedrops containing cannabinoids or cannabinoid strings.  Additionally, upon effectiveness, Wize shall issue 900,000 shares of its common stock to Cannabics.  The agreement shall expire if the parties have not approved a business plan by June 30, 201...